Literature DB >> 18007036

Interaction between the androgen receptor and a segment of its corepressor SHP.

Natalia Jouravel1, Elena Sablin, Leggy A Arnold, R Kiplin Guy, Robert J Fletterick.   

Abstract

The mechanisms of functional repression of the androgen receptor (AR) are crucial for the regulation of genes involved in physiological development as well as for the progression of prostate cancer. To date, only two in vivo inhibitors of AR-mediated transcription have been identified: DAX-1 and SHP (small heterodimer partner). SHP is a regulatory nuclear receptor (NR) that lacks DNA-binding and activation domains. Using X-ray crystallography, the interaction between peptide segments of the SHP repressor containing LxxLL-like motifs and the ligand-binding domain of AR have been investigated. Under the crystallization conditions used, it was found that of the three NR Boxes present in the SHP protein sequence, only NR Box 2 (LKKIL motif) formed a complex with AR. Determination of the crystal structure revealed that ten amino acids of the SHP peptide (14-mer) are ordered through interactions with AR. Two side chains make unique interactions that were not reported for other AR-peptide complexes. The NR Box 2 of SHP binds to an adaptable hydrophobic groove on the surface of AR in a fashion observed for other NR-LxxLL-like complexes. Comparisons of AR structures bound to coactivator peptides and the SHP peptide revealed structural similarity of their binding sites, suggesting that transcriptional AR activity may be inhibited by SHP by competing with AR coactivators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007036     DOI: 10.1107/S0907444907045702

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  8 in total

1.  Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).

Authors:  Marco Cellanetti; Viswanath Gunda; Li Wang; Antonio Macchiarulo; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2010-09-30       Impact factor: 3.686

2.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

Review 3.  Pharmacology of anabolic steroids.

Authors:  A T Kicman
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 4.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Authors:  X Yuan; C Cai; S Chen; S Chen; Z Yu; S P Balk
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

5.  A Novel Mutation of DAX-1 Associated with Secretory Azoospermia.

Authors:  Lisha Mou; Nie Xie; Lihua Yang; Yuchen Liu; Ruiying Diao; Zhiming Cai; Honggang Li; Yaoting Gui
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Androgen receptor functions in prostate cancer development and progression.

Authors:  Steven P Balk
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

7.  Androgen receptor epigenetics.

Authors:  Changmeng Cai; Xin Yuan; Steven P Balk
Journal:  Transl Androl Urol       Date:  2013-09-01

8.  Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Ting-Wei Lin; Ying-Hsu Chang; Yung-Chia Kuo; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Li-Yu Lee; Wen-Lung Ma; Chun-Cheng Lin; Wen-Guey Wu
Journal:  Oncotarget       Date:  2017-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.